Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANABNASDAQ:AVXLNASDAQ:FATENASDAQ:XNCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$23.32-0.4%$20.62$12.21▼$41.31$685.14M-0.26634,670 shs378,901 shsAVXLAnavex Life Sciences$8.03-2.3%$8.42$3.51▼$14.44$685.54M0.681.20 million shs441,883 shsFATEFate Therapeutics$1.28-8.9%$1.20$0.66▼$5.92$146.12M2.232.25 million shs2.43 million shsXNCRXencor$9.19-2.5%$9.06$7.16▼$27.24$654.06M0.87666,986 shs421,639 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio-0.38%-1.60%+19.90%+39.39%-3.24%AVXLAnavex Life Sciences-2.31%-2.90%-1.71%-14.85%+114.13%FATEFate Therapeutics-8.93%-20.31%+32.81%+35.42%-66.18%XNCRXencor-2.55%-4.77%+12.90%-27.98%-58.27%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANABAnaptysBio1.7841 of 5 stars3.40.00.00.02.71.70.6AVXLAnavex Life Sciences3.9156 of 5 stars3.70.00.04.73.60.80.6FATEFate Therapeutics4.127 of 5 stars3.13.00.04.72.71.70.6XNCRXencor4.1875 of 5 stars3.42.00.03.93.40.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANABAnaptysBio 2.80Moderate Buy$42.3881.71% UpsideAVXLAnavex Life Sciences 3.33Buy$44.00447.95% UpsideFATEFate Therapeutics 2.22Hold$4.14224.93% UpsideXNCRXencor 2.89Moderate Buy$29.50221.00% UpsideCurrent Analyst Ratings BreakdownLatest FATE, ANAB, XNCR, and AVXL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2025FATEFate TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold6/4/2025ANABAnaptysBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$22.00 ➝ $38.005/29/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$40.005/28/2025ANABAnaptysBioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.00 ➝ $90.005/14/2025FATEFate TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$10.00 ➝ $2.005/14/2025FATEFate TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$5.00 ➝ $4.005/14/2025FATEFate TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/8/2025XNCRXencorBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$22.00 ➝ $6.005/6/2025ANABAnaptysBioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$52.00 ➝ $54.005/1/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$40.00 ➝ $40.004/30/2025XNCRXencorWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$31.00(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANABAnaptysBio$111.87M6.12N/AN/A$3.32 per share7.02AVXLAnavex Life SciencesN/AN/AN/AN/A$1.42 per shareN/AFATEFate Therapeutics$13.34M10.96N/AN/A$3.74 per share0.34XNCRXencor$127.23M5.14N/AN/A$10.99 per share0.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANABAnaptysBio-$163.62M-$4.85N/AN/AN/A-289.75%-287.94%-37.25%8/4/2025 (Estimated)AVXLAnavex Life Sciences-$43M-$0.55N/AN/AN/AN/A-37.50%-34.08%8/5/2025 (Estimated)FATEFate Therapeutics-$160.93M-$1.49N/AN/AN/A-1,325.43%-45.88%-33.95%8/12/2025 (Estimated)XNCRXencor-$126.09M-$3.06N/AN/AN/A-232.77%-30.92%-21.74%8/4/2025 (Estimated)Latest FATE, ANAB, XNCR, and AVXL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q2 2025AVXLAnavex Life Sciences-$0.16-$0.13+$0.03-$0.13N/AN/A5/13/2025Q1 2025FATEFate Therapeutics-$0.39-$0.32+$0.07-$0.32$1.18 million$1.63 million5/8/2025Q1 2025XNCRXencor-$0.60-$0.66-$0.06-$0.66$23.44 million$32.73 million5/5/2025Q1 2025ANABAnaptysBio-$1.30-$1.28+$0.02-$1.28$15.27 million$27.77 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANABAnaptysBioN/AN/AN/AN/AN/AAVXLAnavex Life SciencesN/AN/AN/AN/AN/AFATEFate TherapeuticsN/AN/AN/AN/AN/AXNCRXencorN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANABAnaptysBioN/A10.2310.23AVXLAnavex Life SciencesN/A9.459.45FATEFate TherapeuticsN/A8.298.29XNCRXencor0.016.236.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANABAnaptysBioN/AAVXLAnavex Life Sciences31.55%FATEFate Therapeutics97.54%XNCRXencorN/AInsider OwnershipCompanyInsider OwnershipANABAnaptysBio33.50%AVXLAnavex Life Sciences11.40%FATEFate Therapeutics5.51%XNCRXencor4.76%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANABAnaptysBio10029.38 million20.17 millionOptionableAVXLAnavex Life Sciences4085.37 million75.71 millionOptionableFATEFate Therapeutics550114.60 million108.20 millionOptionableXNCRXencor28071.17 million66.32 millionOptionableFATE, ANAB, XNCR, and AVXL HeadlinesRecent News About These CompaniesAnalysts Set Xencor, Inc. (NASDAQ:XNCR) Target Price at $29.50June 11 at 3:41 AM | americanbankingnews.comXencor (NASDAQ:XNCR) Trading Up 6.3% - Here's What HappenedJune 10, 2025 | marketbeat.comBank of America Corp DE Sells 585,930 Shares of Xencor, Inc. (NASDAQ:XNCR)June 9, 2025 | marketbeat.com27,491 Shares in Xencor, Inc. (NASDAQ:XNCR) Acquired by Wellington Management Group LLPJune 8, 2025 | marketbeat.comXencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of "Moderate Buy" from BrokeragesJune 8, 2025 | marketbeat.comPublic Employees Retirement System of Ohio Purchases New Holdings in Xencor, Inc. (NASDAQ:XNCR)June 3, 2025 | marketbeat.comXencor, Inc. (NASDAQ:XNCR) Shares Sold by Two Sigma Investments LPMay 27, 2025 | marketbeat.comNuveen Asset Management LLC Purchases 685,557 Shares of Xencor, Inc. (NASDAQ:XNCR)May 26, 2025 | marketbeat.comXencor, Inc. (NASDAQ:XNCR) Holdings Lowered by Jane Street Group LLCMay 26, 2025 | marketbeat.comTwo Sigma Advisers LP Sells 130,900 Shares of Xencor, Inc. (NASDAQ:XNCR)May 25, 2025 | marketbeat.comAmeriprise Financial Inc. Has $6.72 Million Stake in Xencor, Inc. (NASDAQ:XNCR)May 25, 2025 | marketbeat.comXencor, Inc. (NASDAQ:XNCR) Shares Acquired by RTW Investments LPMay 18, 2025 | marketbeat.comPoint72 Asset Management L.P. Sells 943,148 Shares of Xencor, Inc. (NASDAQ:XNCR)May 18, 2025 | marketbeat.comNorthern Trust Corp Increases Holdings in Xencor, Inc. (NASDAQ:XNCR)May 17, 2025 | marketbeat.comXencor, Inc. (NASDAQ:XNCR) Given Average Recommendation of "Moderate Buy" by BrokeragesMay 16, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Raises Stock Position in Xencor, Inc. (NASDAQ:XNCR)May 15, 2025 | marketbeat.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Clover Health Investments (CLOV), Xencor (XNCR) and Intellia Therapeutics (NTLA)May 13, 2025 | theglobeandmail.comXencor Reports First Quarter 2025 Financial ResultsMay 7, 2025 | uk.finance.yahoo.comXencor (XNCR) Reports Q1 Loss, Tops Revenue EstimatesMay 7, 2025 | zacks.comXencor, Inc. (NASDAQ:XNCR) EVP Nancy Valente Sells 4,616 SharesMay 7, 2025 | insidertrades.comWill Xencor (XNCR) Report Negative Q1 Earnings? What You Should KnowMay 1, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsIn a Historic Shift, 2 Cybersecurity Stocks Plan to Buyback StockBy Leo Miller | June 9, 2025View In a Historic Shift, 2 Cybersecurity Stocks Plan to Buyback StockFATE, ANAB, XNCR, and AVXL Company DescriptionsAnaptysBio NASDAQ:ANAB$23.32 -0.09 (-0.38%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$23.32 +0.00 (+0.02%) As of 06/13/2025 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Anavex Life Sciences NASDAQ:AVXL$8.03 -0.19 (-2.31%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$7.96 -0.06 (-0.81%) As of 06/13/2025 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Fate Therapeutics NASDAQ:FATE$1.27 -0.13 (-8.93%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.28 +0.00 (+0.08%) As of 06/13/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.Xencor NASDAQ:XNCR$9.19 -0.24 (-2.55%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$9.18 0.00 (-0.05%) As of 06/13/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
